BIM

115.8

+0.7%↑

SRT3

227.9

+2.24%↑

GXI

57.6

+0.44%↑

ICAD

20.72

-0.48%↓

BIM

115.8

+0.7%↑

SRT3

227.9

+2.24%↑

GXI

57.6

+0.44%↑

ICAD

20.72

-0.48%↓

BIM

115.8

+0.7%↑

SRT3

227.9

+2.24%↑

GXI

57.6

+0.44%↑

ICAD

20.72

-0.48%↓

BIM

115.8

+0.7%↑

SRT3

227.9

+2.24%↑

GXI

57.6

+0.44%↑

ICAD

20.72

-0.48%↓

BIM

115.8

+0.7%↑

SRT3

227.9

+2.24%↑

GXI

57.6

+0.44%↑

ICAD

20.72

-0.48%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

51.35 0.59

Résumé

Variation du prix de l'action

24h

Actuel

Min

50.65

Max

51.4

Chiffres clés

By Trading Economics

Revenu

-57M

32M

Ventes

199M

434M

P/E

Moyenne du Secteur

18.367

57.333

BPA

0.457

Rendement du dividende

2.25

Marge bénéficiaire

7.411

Employés

2,197

EBITDA

40M

138M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+51.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.25%

2.63%

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-896M

2.5B

Ouverture précédente

50.76

Clôture précédente

51.35

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2025, 23:53 UTC

Actions en Tendance

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29 avr. 2025, 23:06 UTC

Résultats

Prudential PLC 1Q New Business Profit Increases by 12%

29 avr. 2025, 23:00 UTC

Résultats

America Movil's Posts Rise in 1Q Profit, Revenue

30 avr. 2025, 00:00 UTC

Actualités

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29 avr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29 avr. 2025, 23:43 UTC

Market Talk

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29 avr. 2025, 23:41 UTC

Résultats

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29 avr. 2025, 23:41 UTC

Résultats

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29 avr. 2025, 23:41 UTC

Résultats

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29 avr. 2025, 23:24 UTC

Résultats

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke 1Q Loss Widened Significantly >000002.SZ

29 avr. 2025, 23:15 UTC

Actualités

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines 1Q Loss Widened >0670.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines Swung to Loss in 1Q>1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29 avr. 2025, 23:07 UTC

Résultats

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29 avr. 2025, 23:07 UTC

Résultats

Air China 1Q Losses Widened>0753.HK

29 avr. 2025, 23:07 UTC

Résultats

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29 avr. 2025, 23:02 UTC

Résultats

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29 avr. 2025, 23:02 UTC

Résultats

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29 avr. 2025, 23:02 UTC

Résultats

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

51.86% hausse

Prévisions sur 12 Mois

Moyen 77.75 EUR  51.86%

Haut 90 EUR

Bas 65.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

49.58 / 51.4Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.